NEW YORK, Dec. 19, 2016 /PRNewswire/ -- Closed Drug Transfer Systems to 2022 - Devices, Markets, Players, and Forecasts
The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues.
Studies of nurses who work with cytotoxic drugs on a regular basis have found a statistically higher rate of spontaneous abortion. Several companies are responding to this unmet need by commercializing devices for closed transfer of these drugs. As the market evolves and user acceptance increases, so too will the impact of these products on oncology therapy protocols and drug delivery
Market-driven Product Strategies
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumercompatible form of packaging and application.
What You Will Learn
- What are the key segments and addressable markets that comprise the market for cytotoxic drug delivery?
- What are the major therapeutic demand drivers for cytotoxic drug therapeutics?
- What are the design factors and technologies that are being used in commercial and development-stage closed drug transfer systems?
- What is the market share and product position in the market and what will it look like in 2020?
- Who are the companies behind the current generation of cytotoxic transfer solutions and what are their business models?
- What is the role of pharma-device alliances and design partnerships in the commercialization and market access of new and emerging closed drug transfer systems?
- What is the impact of economic, technology, and regulatory factors?
Report Value Chain – Who Should Read this Report
- Drug Developers
- Device Suppliers
- Clinical Trial Mgmt
- Pharma Managers
- Biotech Managers
- Drug Marketers
- Industry Strategists
- Financial Analysts
- Management Consultants
- Clinical Managers
- Drug Distributors
- Pharma Regulators
- FDA Consultants
- Managed Care Managers
Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.
Read the full report: http://www.reportlinker.com/p02317746-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/closed-drug-transfer-systems-to-2022-300381322.html